Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma (HCC)

Trial Identifier: D419CR00030
Sponsor: AstraZeneca
Start Date: June 2023
Primary Completion Date: December 2025
Study Completion Date: March 2026
Condition: Liver Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
DE Berlin, DE, D-13353
DE Frankfurt, DE, 60488
DE Köln, DE, 50937
DE Lübeck, DE, 23538
ES Barcelona, ES, 8035
ES Córdoba, ES, 14004
ES Madrid, ES, 28040
ES Madrid, ES, 28007
ES Pamplona, ES, 31008
FR Bobigny, FR, 93000
FR Clichy, FR, 92110
FR Creteil, FR, 94010
FR Marseille, FR, 13005
FR Rennes, FR, 35000
HK Shatin, HK, 00000
IT Milano, IT, 20132
IT Napoli, IT, 80147
IT Padova, IT, 35128
IT Pisa, IT, 56126
IT Rozzano, IT, 20089
IT Turin, IT, 10128
JP Kanazawa-shi, JP, 920-8641
JP Kashiwa, JP, 277-8577
JP Matsuyama-city, JP, 790-0024
JP Musashino-shi, JP, 180-8610
JP Osakasayama-shi, JP, 589-8511
JP Yokohama-shi, JP, 241-8515
KR Gyeonggi-do, KR, 13620
KR Seongnam-si, KR, 13496
KR seoul, KR, 06351
KR Seoul, KR, 03722
KR Seoul, KR, 05505
SG Singapore, SG, 119228
SG Singapore, SG, 308433
SG Singapore, SG, 169610
US, CA La Jolla, CA, US, 92093
US, LA Shreveport, LA, US, 71103
US, MI Detroit, MI, US, 48202